Abstract:Abstract The tumor suppressor TP53 is the most commonly mutated gene in human cancers and mutant p53 has a gain of function by promoting tumor progression, metastasis, and resistance to anticancer therapy. Interestingly, the RNA binding protein Rbm38, a critical regulator of mutant p53 translation, is frequently lost in tumors with mutant p53. To determine the role of the Rbm38-mutant p53 axis in tumorigenesis, we showed that loss of Rbm38 significantly alters the cancer susceptibility of mutant p53 knockin mice by shortening the lifespan, altering the tumor incidence, and promoting T-cell lymphomagenesis. To understand how Rbm38 deficiency promotes mutant p53 gain of function, we showed that loss of Rbm38 not only enhances mutant p53 expression but also decreases expression of tumor suppressor Pten, a critical regulator of T-cell development. Furthermore, we showed that Rbm38 is required for Pten expression by stabilizing Pten mRNA through an AU-rich element in its 3'UTR. Thus, we have uncovered a novel mechanism by which Pten is regulated by Rbm38 via mRNA stability. Our data also suggest that Rbm38 controls T-cell lymphomagenesis by concomitantly modulating mutant p53 and Pten, which may be explored as a therapeutic strategy for the treatment of T-cell malignancies. Citation Format: Jin Zhang, Heejung yang, Yanhong Zhang, Mingyi Chen, Xinbin Chen. Loss of Rbm38 cooperates with mutant p53 to promote lymphomagenesis through downregulation of Pten [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2988.

Mutant P53 Gains Its Function Via C-Myc Activation Upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding

Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Gain-of-function mutant p53 in cancer progression and therapy

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Gain-of-function Mutant P53 Activates Small GTPase Rac1 Through SUMOylation to Promote Tumor Progression

Modeling the Etiology of p53-mutated Cancer Cells

Mutant p53 in Cancer Progression and Targeted Therapies

Wild-Type P53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation.

A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction

Mutant P53 Drives Cancer Metastasis Via RCP-Mediated Hsp90α Secretion.

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Unequal Prognostic Potentials of P53 Gain-of-function Mutations in Human Cancers Associate with Drug-Metabolizing Activity.

The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

Tumour-associated mutant p53 drives the Warburg effect

Mutant p53 in cancer therapy-the barrier or the path.

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Gain of Function of Mutant P53: R282W on the Peak?

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Cancer Cells Escape P53's Tumor Suppression Through Ablation of ZDHHC1-mediated P53 Palmitoylation